43 results on '"McCune M"'
Search Results
2. Virtual reality for the treatment of post-operative pain after laparoscopic hysterectomy for benign indications
- Author
-
Tufano, S., primary, Mahnert, N., additional, Oelkers, K., additional, Segaline, N., additional, Gill, M., additional, McCune, M., additional, and Foote, J., additional
- Published
- 2022
- Full Text
- View/download PDF
3. FP09.03 Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis
- Author
-
Moore, Z., primary, Lobaugh, S., additional, Zhang, Z., additional, Geyer, A., additional, Gelblum, D., additional, Abdulnour, R., additional, Shepherd, A., additional, Shaverdian, N., additional, Mccune, M., additional, Li, H., additional, Wu, A., additional, Simone, Ii, C., additional, Mak, R., additional, Weinhouse, G., additional, Liao, Z., additional, Gomez, D., additional, Paik, P., additional, and Rimner, A., additional
- Published
- 2021
- Full Text
- View/download PDF
4. MA06.08 A Safety Study of Avelumab plus SBRT in Malignant Mesothelioma
- Author
-
Rimner, A., primary, Yorke, E., additional, Gelblum, D., additional, Shepherd, A., additional, Guttmann, D., additional, Iqbal, A., additional, Daly, R., additional, Offin, M., additional, Fiore, J., additional, Namakydoust, A., additional, Li, H., additional, Mccune, M., additional, Gelb, E., additional, Taunk, N., additional, Von Reibnitz, D., additional, Adusumilli, P., additional, Center, M.S.K., additional, and Zauderer, M., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Durvalumab with Concurrent Definitive Radiation Therapy (DART) for Locally-Advanced Non-Small Cell Lung Cancer - A Phase II Study
- Author
-
Rimner, A., primary, Offin, M., additional, Shaverdian, N., additional, McKnight, D., additional, Li, H., additional, Mccune, M., additional, Patson, B., additional, Kotecha, R., additional, Gomez, D.R., additional, and Chaft, J., additional
- Published
- 2020
- Full Text
- View/download PDF
6. Gunter Blobel: Pioneer of molecular cell biology (1936-2018)
- Author
-
Aitchison, JD, Albertini, M, Anderson, DJ, Aronow, B, Beckmann, R, Bera, M, Bergamin, E, Berman, D, Berrios, M, Blus, B, Bonatti, S, Bonifaci, N, Borgese, N, Chaudhary, N, Chauhan, R, Chaves, S, Chirico, WJ, Chook, Y, Conner, G, Courvalin, J-C, Coutavas, E, Debler, E, Denisenko, N, Devillers-Thiery, A, Fletcher, MD, Djabali, K, Dobberstein, B, Dwyer, N, Enenkel, C, Enninga, J, Erdmann, R, Erickson, A, Fan, J, Bridger, IF, Filson, A, Fisher, D, Fisher, RP, Fletcher, P, Floer, M, Fontoura, B, Friedlander, M, Gerace, L, Gilmore, R, Giudice, L, Gnadig, M, Gray, L, Greenburg, G, Hallberg, E, Hao, Q, Helmers, J, Hijikata, M, Hoelz, A, Hoiczyk, E, Hsia, K-C, Hunt, J, Hurwitz, M, Isberto, T, Johnson, E, Kampmann, M, Kaput, J, Katz, E, Kessler, F, Kim, HB, King, M, Koch-Brandt, C, Koh, J, Kraemer, D, Krolak, A, Li, X, Lingappa, VR, Lingappa, J, Lusk, P, Ma, Y, Matunis, MJ, McCune, M, Meier, T, Melcak, I, Mitchell, C, Moore, M, Moroianu, J, Muller, M, Nagy, V, Napetschnig, J, Nerhbass, U, Nicchitta, C, Nigam, SK, Nimic, G, Pain, D, Quirolgico, LR, Rahman, M, Ren, Y, Roa, M, Rout, MP, Schmidt, D, Schnell, D, Schuelke, N, Schwartz, T, Seo, H-S, Sharma, A, Shelness, G, Simon, S, Singh, N, Smith, S, Solmaz, SR, De Castillia, CS, Sun, J, Titov, A, Urnavicius, L, Wacker, D, Walter, P, Waters, G, Wente, SR, Wing, RA, Wong, R, Worman, H, Wozniak, RW, YaDeau, J, Yaseen, N, Yoshida, K, Zhao, X, and Zhong, H
- Published
- 2018
- Full Text
- View/download PDF
7. Ballots, Babies, and Banners of Peace: American Jewish Women's Activism, 1890-1940
- Author
-
McCune, M., primary
- Published
- 2014
- Full Text
- View/download PDF
8. All Together Different: Yiddish Socialists, Garment Workers, and the Labor Roots of Multiculturalism
- Author
-
McCune, M., primary
- Published
- 2012
- Full Text
- View/download PDF
9. ARTS BETA testing report
- Author
-
Mccune, M. C
- Subjects
Computer Systems - Abstract
The advanced real time system (ARTS) was tested utilizing existing commercial system hardware and software which has been operating under advanced operating system (AOS) for several years in a multitasking, multiprocessing, and multiple computer environment. Experiences with ARTS in terms of compatibility with AOS, ease of transmission between AOS and ARTS, and functional areas of ARTS which were tested are discussed. Relative and absolute performance of ARTS versus AOS as measured in the system environment are also presented.
- Published
- 1981
10. Initial test results of 40,000 horsepower fan drive gear system for advanced ducted propulsion systems
- Author
-
MCCUNE, M., primary
- Published
- 1993
- Full Text
- View/download PDF
11. VIRTUAL LOLLIPOPS AND LOST PUPPIES: HOW FAR CAN STATES GO TO PROTECT MINORS THROUGH THE USE OF INTERNET LURING LAWS.
- Author
-
McCune, M. Megan
- Subjects
INTERNET & teenagers ,INTERNET pornography ,INTERNET laws ,LEGISLATIVE bills ,LEGISLATION ,COMPUTER sex ,INTERNET ,GOVERNMENT policy - Abstract
The article presents a discussion on the victimization of youth on the Internet and Internet luring and examines ways in which Congress has attempted to provide widespread Internet protection for the youth. It also discussed actions undertaken by individual states to protect youth on the Internet which include enacting content-based regulations and statutes to prevent Internet luring. It also showed how the proposed amendment to California's Internet luring law did not survive constitutional scrutiny and proposed amendment to the Internet luring legislation in order to provide more protection for the youth on the Internet.
- Published
- 2006
12. High‐beta operation and magnetohydrodynamic activity on the TFTR tokamak
- Author
-
McGuire, K., primary, Arunasalam, V., additional, Barnes, C. W., additional, Bell, M. G., additional, Bitter, M., additional, Boivin, R., additional, Bretz, N. L., additional, Budny, R., additional, Bush, C. E., additional, Cavallo, A., additional, Chu, T. K., additional, Cohen, S. A., additional, Colestock, P., additional, Davis, S. L., additional, Dimock, D. L., additional, Dylla, H. F., additional, Efthimion, P. C., additional, Ehrhrardt, A. B., additional, Fonck, R. J., additional, Fredrickson, E., additional, Furth, H. P., additional, Gammel, G., additional, Goldston, R. J., additional, Greene, G., additional, Grek, B., additional, Grisham, L. R., additional, Hammett, G., additional, Hawryluk, R. J., additional, Hendel, H. W., additional, Hill, K. W., additional, Hinnov, E., additional, Hoffman, D. J., additional, Hosea, J., additional, Howell, R. B., additional, Hsuan, H., additional, Hulse, R. A., additional, Janos, A. C., additional, Jassby, D., additional, Jobes, F., additional, Johnson, D. W., additional, Johnson, L. C., additional, Kaita, R., additional, Kieras‐Phillips, C., additional, Kilpatrick, S. J., additional, LaMarche, P. H., additional, LeBlanc, B., additional, Manos, D. M., additional, Mansfield, D. K., additional, Mazzucato, E., additional, McCarthy, M. P., additional, McCune, M. C., additional, McNeill, D. H., additional, Meade, D. M., additional, Medley, S. S., additional, Mikkelsen, D. R., additional, Monticello, D., additional, Motley, R., additional, Mueller, D., additional, Murphy, J. A., additional, Nagayama, Y., additional, Nazakian, D. R., additional, Neischmidt, E. B., additional, Owens, D. K., additional, Park, H., additional, Park, W., additional, Pitcher, S., additional, Ramsey, A. T., additional, Redi, M. H., additional, Roquemore, A. L., additional, Rutherford, P. H., additional, Schilling, G., additional, Schivell, J., additional, Schmidt, G. L., additional, Scott, S. D., additional, Sinnis, J. C., additional, Stevens, J., additional, Stratton, B. C., additional, Stodiek, W., additional, Synakowski, E. J., additional, Tang, W. M., additional, Taylor, G., additional, Timberlake, J. R., additional, Towner, H. H., additional, Ulrickson, M., additional, von Goeler, S., additional, Wieland, R., additional, Williams, M., additional, Wilson, J. R., additional, Wong, K.‐L., additional, Yamada, M., additional, Yoshikawa, S., additional, Young, K. M., additional, Zarnstorff, M. C., additional, and Zweben, S. J., additional
- Published
- 1990
- Full Text
- View/download PDF
13. Engine Prime Mover Automation
- Author
-
McCune, M. K.
- Abstract
“Full range” automation control of engine prime movers makes possible the direct conversion of primary fuel sources of liquid or gaseous types to prime mover power with the labor savings advantages of unattended automated operation. This paper outlines the development of the “full range” automation program control with related “slave” control devices as required for the overall automated system, and reviews some requirements for a successful engine automation program.
- Published
- 1970
- Full Text
- View/download PDF
14. Engine Prime Mover Automation
- Author
-
McCune, M. K., primary
- Published
- 1970
- Full Text
- View/download PDF
15. Closure to “Discussion of ‘Engine Prime Mover Automation’” (1970, ASME J. Eng. Power, 92, p. 106)
- Author
-
McCune, M. K., primary
- Published
- 1970
- Full Text
- View/download PDF
16. Closure to “Discussion of ‘Engine Prime Mover Automation’” (1970, ASME J. Eng. Power, 92, p. 106)
- Author
-
McCune, M. K.
- Published
- 1970
- Full Text
- View/download PDF
17. Racial disparities in length of hospitalization and systemic medication utilization in patients with psoriasis.
- Author
-
Desai R, Irwin C, McCune M, and Davis M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, United States epidemiology, Aged, Young Adult, Hospitalization statistics & numerical data, Adolescent, Psoriasis drug therapy, Length of Stay statistics & numerical data, Healthcare Disparities statistics & numerical data
- Abstract
The growing evidence of chronic inflammation and sequelae caused by psoriasis indicates the need for systemic treatment, including biologics and conventional treatments like methotrexate. However, unconscious racial bias may lead to discrepancies in systemic medication prescription. Racial identity is also suspected to affect comorbidity and hospitalization rates in patients with psoriasis. This study examines the impact of race on hospitalization duration and systemic medication prescription patterns in patients with psoriasis in the United States in 2020. The 2020 Healthcare Cost and Utilization (HCUP) National Inpatient Sample (NIS) database was used, with inpatient admissions over the age of 17 with an ICD-10-coded psoriasis diagnosis included. Patient demographics and hospital characteristics were compared between "non-white" and "white" patients, with white patients as the reference group. The primary outcome, systemic medication prescription, was evaluated using logistic regression models, producing an odds ratio and corresponding 95% confidence interval (CI). The secondary outcome, length of stay, was evaluated using negative binomial regression models to approximate the incident rate ratio and 95% CI. 1,802,720 patients with psoriasis were included in this study. Hispanic, Asian or Pacific Islander, and Native American patients with psoriasis had significantly lower odds of systemic medication prescription than white patients with psoriasis. All non-white racial identities were found to have significantly longer estimated lengths of stay compared to white patients with psoriasis. Disparities in the medication of choice for psoriasis treatment can lead to increased inpatient burden with longer lengths of stay for non-white patients., Competing Interests: Declarations. Conflicts of interest: The authors declare no competing interests. Ethical approval: This is a retrospective observational study, so no ethics approval is required., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
18. Correction: A quantitative wildfire risk assessment using a modular approach of geostatistical clustering and regionally distinct valuations of assets-A case study in Oregon.
- Author
-
Schmidt A, Leavell D, Punches J, Rocha Ibarra MA, Kagan JS, Creutzburg M, McCune M, Salwasser J, Walter C, and Berger C
- Abstract
[This corrects the article DOI: 10.1371/journal.pone.0264826.]., (Copyright: © 2024 Schmidt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
19. Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial.
- Author
-
Rimner A, Gelblum DY, Wu AJ, Shepherd AF, Mueller B, Zhang S, Cuaron J, Shaverdian N, Flynn J, Fiasconaro M, Zhang Z, von Reibnitz D, Li H, McKnight D, McCune M, Gelb E, Gomez DR, Simone CB 2nd, Deasy JO, Yorke ED, Ng KK, and Chaft JE
- Subjects
- Humans, Male, Aged, Female, Aged, 80 and over, Middle Aged, Neoplasm Staging, Disease Progression, Dose Fractionation, Radiation, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung mortality, Radiosurgery adverse effects, Radiosurgery methods, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Lung Neoplasms mortality, Maximum Tolerated Dose
- Abstract
Purpose: Larger tumors are underrepresented in most prospective trials on stereotactic body radiation therapy (SBRT) for inoperable non-small cell lung cancer (NSCLC). We performed this phase 1 trial to specifically study the maximum tolerated dose (MTD) of SBRT for NSCLC >3 cm., Methods and Materials: A 3 + 3 dose-escalation design (cohort A) with an expansion cohort at the MTD (cohort B) was used. Patients with inoperable NSCLC >3 cm (T2-4) were eligible. Select ipsilateral hilar and single-station mediastinal nodes were permitted. The initial SBRT dose was 40 Gy in 5 fractions, with planned escalation to 50 and 60 Gy in 5 fractions. Adjuvant chemotherapy was mandatory for cohort A and optional for cohort B, but no patients in cohort B received chemotherapy. The primary endpoint was SBRT-related acute grade (G) 4+ or persistent G3 toxicities (Common Terminology Criteria for Adverse Events version 4.03). Secondary endpoints included local failure (LF), distant metastases, disease progression, and overall survival., Results: The median age was 80 years; tumor size was >3 cm and ≤5 cm in 20 (59%) and >5 cm in 14 patients (41%). In cohort A (n = 9), 3 patients treated to 50 Gy experienced G3 radiation pneumonitis (RP), thus defining the MTD. In the larger dose-expansion cohort B (n = 25), no radiation therapy-related G4+ toxicities and no G3 RP occurred; only 2 patients experienced G2 RP. The 2-year cumulative incidence of LF was 20.2%, distant failure was 34.7%, and disease progression was 54.4%. Two-year overall survival was 53%. A biologically effective dose (BED) <100 Gy was associated with higher LF (P = .006); advanced stage and higher neutrophil/lymphocyte ratio were associated with greater disease progression (both P = .004)., Conclusions: Fifty Gy in 5 fractions is the MTD for SBRT to tumors >3 cm. A higher BED is associated with fewer LFs even in larger tumors. Cohort B appears to have had less toxicity, possibly due to the omission of chemotherapy., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. The incidence of infratentorial arteriovenous malformation-associated aneurysms: an institutional case series and systematic literature review.
- Author
-
Davison M, McCune M, Thiyagarajah N, Kashkoush A, Achey R, Shost M, Toth G, Bain M, and Moore N
- Abstract
Background: Arteriovenous malformation (AVM)-associated aneurysms represent a high-risk feature predisposing them to rupture. Infratentorial AVMs have been shown to have a greater incidence of associated aneurysms, however the existing data is outdated and biased. The aim of our research was to compare the incidence of supratentorial vs infratentorial AVM-associated aneurysms., Methods: Patients were identified from our institutional AVM registry, which includes all patients with an intracranial AVM diagnosis since 2000, regardless of treatment. Records were reviewed for clinical details, AVM characteristics, nidus location (supratentorial or infratentorial), and presence of associated aneurysms. Statistical comparisons were made using Fisher's exact or Wilcoxon rank sum tests as appropriate. Multivariable logistic regression analysis determined independent predictors of AVM-associated aneurysms. As a secondary analysis, a systematic literature review was performed, where studies documenting the incidence of AVM-associated aneurysms stratified by location were of interest., Results: From 2000-2024, 706 patients with 720 AVMs were identified, of which 152 (21.1%) were infratentorial. Intracranial hemorrhage was the most common AVM presentation (42.1%). The incidence of associated aneurysms was greater in infratentorial AVMs compared with supratentorial cases (45.4% vs 20.1%; P<0.0001). Multivariable logistic regression demonstrated that infratentorial nidus location was the singular predictor of an associated aneurysm, odds ratio: 2.9 (P<0.0001). Systematic literature review identified eight studies satisfying inclusion criteria. Aggregate analysis indicated infratentorial AVMs were more likely to harbor an associated aneurysm (OR 1.7) and present as ruptured (OR 3.9), P<0.0001., Conclusions: In this modern consecutive patient series, infratentorial nidus location was a significant predictor of an associated aneurysm and hemorrhagic presentation., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
21. Reactive Granulomatous Dermatitis in a Child with Acute Lymphoblastic Leukemia.
- Author
-
Tolson HC, McCune M, Yousif M, DiCaudo D, and Dupuy E
- Abstract
Reactive granulomatous dermatitis (RGD) is an umbrella term to describe a reaction pattern characterized by skin-colored to erythematous papules, plaques, and nodules although other morphologies have been described. RGD has rarely been reported in children, and in this report, we present the case of a 3-year-old girl with acute lymphoblastic leukemia (ALL) who presented with firm, tender nodules, and ulcerated plaques on her extremities. Histopathologic examination showed foci of dense granulomatous inflammatory infiltrates composed of histiocytes, neutrophils, and multinucleate giant cells. The constellation of clinical symptoms, negative infectious workup, and histopathology support the diagnosis of RGD., Competing Interests: The authors declare that there are no conflicts of interest., (Copyright © 2023 Hannah C. Tolson et al.)
- Published
- 2023
- Full Text
- View/download PDF
22. Virtual reality for the treatment of postoperative pain after laparoscopic hysterectomy for benign Indications: A randomized controlled trial.
- Author
-
McCune M, Tufano S, Gill M, Oelkers K, Segaline N, Foote J, Aguirre A, and Mahnert ND
- Subjects
- Female, Humans, Pain, Postoperative drug therapy, Pain, Postoperative etiology, Hysterectomy adverse effects, Narcotics, Laparoscopy adverse effects, Virtual Reality
- Abstract
Objective: The primary objective of this study was to determine if immediate post-operative use of virtual reality impacts pain scores or opioid consumption following hysterectomy., Study Design: A randomized controlled trial was performed at a university associated tertiary referral hospital in the United States among patients undergoing laparoscopic hysterectomy for benign indications. Prior to surgery, participants were randomized to use a VR program versus routine care postoperatively in the post anesthesia care unit. Postoperative pain was measured using visual analogue scale, and morphine milligram equivalent to quantify narcotic usage. Patient satisfaction was assessed with a survey. A total of 15 patients were randomized to the virtual reality intervention and 15 to the standard care group. The test statistic was a one-sided T-test, with a significance level targeted of 0.05. Categorical variables were analyzed using chi-square analysis and t-test for continuous variables. Pain score differences between the virtual reality and standard care groups at each time assessment were compared using the Wilcoxon Rank Sum test., Results: The use of virtual reality did not significantly affect pain scores or postoperative narcotics required; however, it did have a positive impact on the subject's perception of their postoperative course. No adverse events were reported., Conclusion: Although virtual reality use following hysterectomy did not improve pain scores or decrease narcotic usage, it was well received by patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
- Author
-
Lebow ES, Shaverdian N, Eichholz JE, Kratochvil LB, McCune M, Murciano-Goroff YR, Jee J, Eng J, Chaft JE, Kris MG, Kalashnikova E, Feeney J, Scalise CB, Sudhaman S, Palsuledesai CC, Malhotra M, Krainock M, Sethi H, Aleshin A, Liu MC, Shepherd AF, Wu AJ, Simone CB 2nd, Gelblum DY, Johnson KA, Rudin CM, Gomez DR, Razavi P, Reis-Filho JS, Isbell JM, Li BT, and Rimner A
- Abstract
Background: Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced non-small cell lung cancer (NSCLC) who are treated with definitive radiation therapy (RT). This prospective, multistate single-center, cohort study investigated the association of circulating tumor DNA (ctDNA) status with recurrence in patients with unresectable stage I-III NSCLC who underwent definitive RT., Methods: A total of 70 serial plasma samples from 17 NSCLC patients were collected before, during, and after treatment. A personalized, tumor-informed ctDNA assay was used to track a set of up to 16 somatic, single nucleotide variants in the associated patient's plasma samples., Results: Pre-treatment ctDNA detection rate was 82% (14/17) and varied based on histology and stage. ctDNA was detected in 35% (6/17) of patients at the first post-RT timepoint (median of 1.66 months following the completion of RT), all of whom subsequently developed clinical progression. At this first post-RT time point, patients with ctDNA-positivity had significantly worse progression-free survival (PFS) [hazard ratio (HR): 24.2, p=0.004], and ctDNA-positivity was the only significant prognostic factor associated with PFS (HR: 13.4, p=0.02) in a multivariate analysis. All patients who developed clinical recurrence had detectable ctDNA with an average lead time over radiographic progression of 5.4 months, and post-RT ctDNA positivity was significantly associated with poor PFS (p<0.0001)., Conclusion: Personalized, longitudinal ctDNA monitoring can detect recurrence early in patients with unresectable NSCLC patients undergoing curative radiation and potentially risk-stratify patients who might benefit most from treatment intensification., Competing Interests: NS reports research funding from Novartis. DG reports research funding from Astra Zeneca and Varian and receives Honoraria from Johnson and Johnson, MedLearning Gropu, and GRAIL. YM-G reports travel, accommodation, and expenses from AstraZeneca and Loxo Oncology/Eli Lilly. She acknowledges honoraria from Virology Education and Projects in Knowledge for a CME program funded by an educational grant from Amgen. She acknowledges associated research funding to the institution from Mirati Therapeutics, Loxo Oncology at Eli Lilly, Elucida Oncology, Taiho Oncology, Hengrui USA, Ltd/Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, and Endeavor Biomedicines. She acknowledges royalties from Rutgers University Press and Wolters Kluwer. She acknowledges food/beverages from Endeavor Biomedicines. YM-G acknowledges receipt of training through an institutional K30 grant from the NIH CTSA UL1TR00457. She has received funding from a Kristina M. Day Young Investigator Award from Conquer Cancer, the ASCO Foundation, endowed by Dr. Charles M. Baum and Carol A. Baum. She is also funded by the Fiona and Stanley Druckenmiller Center for Lung Cancer Research, the Andrew Sabin Family Foundation, the Society for MSK, and a Paul Calabresi Career Development Award for Clinical Oncology NIH/NCI K12 CA184746. JJ has a patent licensed by MDSeq Inc. JC has served as a consultant for Astra Zeneca, Bristol-Myers Squib, Genentech, Merck, Flame Biosciences, Novartis, Regeneron-Sanofi, Guardant Health, and Janssen as well as received research funding to her institution from Astra Zeneca, Bristol-Myers Squib, Genentech, and Merck. MGK receives personal fees from Novartis, Sanofi-Genzyme, AstraZeneca, Pfizer, Janssen, and Daiichi-Sankyo. He has also received honoraria for participation in educational programs from WebMD, OncLive, Physicians Education Resources, Prime Oncology, Intellisphere, Creative Educational Concepts, Peerview, i3 Health, Paradigm Medical Communications, AXIS, Carvive Systems, and AstraZeneca. MGK has received travel support from AstraZeneca, Pfizer, and Genentech as well as editorial support from Hoffman La-Roche. EK, JF, CBS, SS, CCP, MMa, MK, HS, AA, and MCL reported employment and stock ownership or option at Natera, Inc outside the submitted work. MCL reported receiving grants funding to Mayo Clinic from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics and Tesaro, and travel support from AstraZeneca, Genomic Health and Ionis, outside the submitted work. AS has stock ownership in ArcellX and Doximity. AW reports research support from CivaTech Oncology, Inc, Honoraria from Nanovi A/S, serves on the Scientific Advisory Board of Simphotek, Inc, and has stock in Simphotek, Inc. CS reports Honoraria from Varian and Novocure and serves in a Leadership position for the Proton Collaborative Group, American Society for Radiation Oncology, NRG Oncology, American Radium Society, and Annals of Palliative Medicine. DG reports research funding to her institution from Merck. CR reports personal fees from AbbVie, Amgen, Ascentage, AstraZeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jansen, Jazz, Lilly/Loxo, Pfizer, PharmaMar, Syros, Vavotek, Bridge Medicines, and Harpoon Therapeutics, outside the submitted work. DG reports grants to his institutions from Varian, AstraZeneca, Merck, and Bristol Myers Squibb, personal fees from Varia, AstraZeneca, Merck, US Oncology, Bristol Myers Squibb, Relfexion, WebMD, Vindico, and Medscape; and has served on the advisory board for AstraZeneca; he has also received Honoraria from Johnson and Johnson, MedLearning Group, and GRAIL. PR received institutional grant/funding from Grail, Illumina, Novartis, Epic Sciences, ArcherDx and Consultation/Ad board/Honoraria from Novartis, Foundation Medicine, AstraZeneca, Epic Sciences, Inivata, Natera, and Tempus. JR-F is a paid consultant of Goldman Sachs, Paige.AI and REPARE Therapeutics, a member of the Scientific Advisory Board of Goldman Sachs, Paige.AI and Volition RX, and ad hoc member of the scientific advisory board of Roche, Genetech, Roche Tissue Diagnostics, Ventana, Novartis, InVicro and GRAIL. JR-F reports receiving personal/consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics, Saga Diagnostics and Paige.AI, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Astrazeneca, Merck, Daiichi Sankyo, Roche Tissue Diagnostics and Personalis, outside the scope of this study. JR-F is funded in part by the Breast Cancer Research Foundation, by a Susan G Komen Leadership grant, and by the NIH/NCI P50 CA247749 01 grant. JI reports equity in LumaCyte, LLC and has served as an uncompensated member of a steering committee for Genentech. BL has served as an uncompensated advisor and consultant to Amgen, Genentech, Boehringer Ingelheim, Lilly, AstraZeneca, Daiichi Sankyo. He has received research grants to his institution from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Lilly, Illumina, GRAIL, Guardant Health, Hengrui Therapeutics, MORE Health and Bolt Biotherapeutics. He has received academic travel support from MORE Health, and Jiangsu Hengrui Medicine. He is an inventor on two institutional patents at MSK US62/685,057, US62/514,661 and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. AR reports research funding from Varian Medical Systems, Boehringer Ingelheim, Astra Zeneca, Merck, and Pfizer and serves in Leadership Positions for the International Thymic Malignancies Group and International Mesothelioma Interest group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lebow, Shaverdian, Eichholz, Kratochvil, McCune, Murciano-Goroff, Jee, Eng, Chaft, Kris, Kalashnikova, Feeney, Scalise, Sudhaman, Palsuledesai, Malhotra, Krainock, Sethi, Aleshin, Liu, Shepherd, Wu, Simone, Gelblum, Johnson, Rudin, Gomez, Razavi, Reis-Filho, Isbell, Li and Rimner.)
- Published
- 2023
- Full Text
- View/download PDF
24. TikTok as a Source of Medical Information: Port Wine Stain Birthmarks and Treatment Using Vascular Lasers.
- Author
-
Tolson H, Wenger D, McCune M, Alzahrani F, and Dupuy E
- Abstract
Background: As social media usage grows, more patients are turning to various platforms to gain and share medical information. One platform, TikTok, has become immensely popular, with over one billion users. Despite its potential use as an educational tool, TikTok can be unreliable and misleading as a medical information source., Objective: We aim to discuss the information available on TikTok regarding laser treatment for port wine stains (PWS)., Methods: Two independent reviewers analyzed 200 TikTok videos with the hashtags #portwinestainlaser or #portwinestaintreatment, examining the video creator's role (e.g., patient, parent, physician, or other), tone towards PWS and treatment options, and content (e.g., educational or non-educational, mention of any treatment risks)., Results: Most videos were produced by non-medical professionals (83%), and only a small number discussed the potential adverse effects of PWS treatment options (15%)., Conclusion: While TikTok may have a role in educating patients about certain dermatologic conditions and treatment options, it is important to encourage patients to seek medical advice from a qualified medical professional before making any treatment decisions. Furthermore, the future of patient education may need to evolve to include social media platforms., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Tolson et al.)
- Published
- 2023
- Full Text
- View/download PDF
25. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
- Author
-
Rimner A, Moore ZR, Lobaugh S, Geyer A, Gelblum DY, Abdulnour RE, Shepherd AF, Shaverdian N, Wu AJ, Cuaron J, Chaft JE, Zauderer MG, Eng J, Riely GJ, Rudin CM, Els NV, Chawla M, McCune M, Li H, Jones DR, Sopka DM, Simone CB 2nd, Mak R, Weinhouse GL, Liao Z, Gomez DR, Zhang Z, and Paik PK
- Subjects
- Humans, Prednisone adverse effects, Disease Progression, Double-Blind Method, Protein Kinase Inhibitors therapeutic use, Radiation Pneumonitis etiology
- Abstract
Purpose: Radiation pneumonitis (RP) is the most common dose-limiting toxicity for thoracic radiation therapy. Nintedanib is used for the treatment of idiopathic pulmonary fibrosis, which shares pathophysiological pathways with the subacute phase of RP. Our goal was to investigate the efficacy and safety of nintedanib added to a prednisone taper compared with a prednisone taper alone in reducing pulmonary exacerbations in patients with grade 2 or higher (G2+) RP., Methods and Materials: In this phase 2, randomized, double-blinded, placebo-controlled trial, patients with newly diagnosed G2+ RP were randomized 1:1 to nintedanib or placebo in addition to a standard 8-week prednisone taper. The primary endpoint was freedom from pulmonary exacerbations at 1 year. Secondary endpoints included patient-reported outcomes and pulmonary function tests. Kaplan-Meier analysis was used to estimate the probability of freedom from pulmonary exacerbations. The study was closed early due to slow accrual., Results: Thirty-four patients were enrolled between October 2015 and February 2020. Of 30 evaluable patients, 18 were randomized to the experimental Arm A (nintedanib + prednisone taper) and 12 to the control Arm B (placebo + prednisone taper). Freedom from exacerbation at 1 year was 72% (confidence interval, 54%-96%) in Arm A and 40% (confidence interval, 20%-82%) in Arm B (1-sided, P = .037). In Arm A, there were 16 G2+ adverse events possibly or probably related to treatment compared with 5 in the placebo arm. There were 3 deaths during the study period in Arm A due to cardiac failure, progressive respiratory failure, and pulmonary embolism., Conclusions: There was an improvement in pulmonary exacerbations by the addition of nintedanib to a prednisone taper. Further investigation is warranted for the use of nintedanib for the treatment of RP., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
26. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma.
- Author
-
Rimner A, Adusumilli PS, Offin MD, Solomon SB, Ziv E, Hayes SA, Ginsberg MS, Sauter JL, Gelblum DY, Shepherd AF, Guttmann DM, Eichholz JE, Zhang Z, Ritter E, Wong P, Iqbal AN, Daly RM, Namakydoust A, Li H, McCune M, Gelb EH, Taunk NK, von Reibnitz D, Tyagi N, Yorke ED, Rusch VW, and Zauderer MG
- Abstract
Introduction: Single-agent monoclonal antibody therapy against programmed death-ligand 1 (PD-L1) has modest effects in malignant pleural mesothelioma. Radiation therapy can enhance the antitumor effects of immunotherapy. Nevertheless, the safety of combining anti-PD-L1 therapy with stereotactic body radiation therapy (SBRT) is unknown. We present the results of a phase 1 trial to evaluate the safety of the anti-PD-L1 antibody avelumab plus SBRT in patients with malignant pleural mesothelioma., Methods: This was a single-arm, investigator-initiated trial in patients who progressed on prior chemotherapy. Avelumab was delivered every other week, and SBRT was delivered to one lesion in three to five fractions (minimum of 30 Gy) followed by continuation of avelumab up to 24 months or until disease progression. The primary end point of the study was safety on the basis of grade 3+ nonhematologic adverse events (AEs) within 3 months of SBRT., Results: Thirteen assessable patients received a median of seven cycles (range: 2-26 cycles) of avelumab. There were 27 grade 1, 17 grade 2, four grade 3, and no grade 4 or 5 avelumab-related AEs. The most common were infusion-related allergic reactions (n = 6), anorexia or weight loss (n = 6), fatigue (n = 6), thyroid disorders (n = 5), diarrhea (n = 3), and myalgia or arthralgias (n = 3). There were 10 grade 1, four grade 2, one grade 3, and no grade 4 or 5 SBRT-related AEs. The most common were diarrhea (n = 3), chest pain/myalgia (n = 2), fatigue (n = 2), cough (n = 2), dyspnea (n = 2), and nausea/vomiting (n = 2)., Conclusions: Combination avelumab plus SBRT seems tolerable on the basis of the prespecified toxicity end points of the first stage of this Simon two-stage design phase 1 study., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
27. A quantitative wildfire risk assessment using a modular approach of geostatistical clustering and regionally distinct valuations of assets-A case study in Oregon.
- Author
-
Schmidt A, Leavell D, Punches J, Rocha Ibarra MA, Kagan JS, Creutzburg M, McCune M, Salwasser J, Walter C, and Berger C
- Subjects
- Cluster Analysis, Oregon, Risk Assessment, Weather, Wildfires
- Abstract
The intensity and scale of wildfires has increased throughout the Pacific Northwest in recent decades, especially within the last decade, destroying vast amounts of valuable resources and assets. This trend is predicted to remain or even magnify due climate change, growing population, increased housing density. Furthermore, the associated stress of prolonged droughts and change in land cover/land use puts more population at risk. We present results of a multi-phase Extension Fire Program Initiative combining fire model results based on worst-case meteorological conditions recorded at 50 weather stations across Oregon with spatially distinct valuations of resources and assets based on regional ecological and socio-economic conditions. Our study focuses on six different Fire Service Areas covering the state of Oregon. We used a geostatistical approach to find weather stations that provide worst-case meteorological input data on record for representative sub-domains. The results provide regionally distinct assessments of potential value loss by wildfire and show that, depending on the region, 12% to 52% of the highest relative risk areas are on private land. This underscores the need to unite strategies and efforts on the landscape scale by including different landowners, managers, and stakeholders of public land and private land efficiently address wildfire damage protection and mitigation. Our risk assessments closely agreed with risks identified during landscape-scale ground projects., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
28. A Multifaceted Approach to Improving Postischemic Stroke Dysphagia Screening at a Community Hospital.
- Author
-
Shenoy AM, McCune M, and AbdelRazek MA
- Subjects
- Hospitals, Community, Humans, Mass Screening, Brain Ischemia, Deglutition Disorders diagnosis, Deglutition Disorders etiology, Stroke complications
- Abstract
Background: Dysphagia is a common complication seen in acute ischemic stroke patients, and can lead to morbidity and mortality. As such, quality measures have been instituted to track adherence to dysphagia screening in all stroke patients. In our 217-bed community hospital, we were faced with a low rate in successfully screening for dysphagia., Methods: Quality control interventions were implemented after an analysis of the reasons for dysphagia screening failures was performed. Interventions included online educational sessions for nurses, face-to-face sessions with medical residents, distribution of educational laminated cards, changing the method of documenting the dysphagia screen in our electronic record and others., Results: There was an increase of rates of screening for dysphagia from 67% to 91%., Conclusion: We conclude that failure analysis, implementation of quality control measures to address the cause of failures and re-evaluating success rates periodically was effective to address this problem., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
29. Measuring executive function skills in young children in Kenya.
- Author
-
Willoughby MT, Piper B, Kwayumba D, and McCune M
- Subjects
- Child, Child, Preschool, Female, Humans, Kenya, Male, Cognition physiology, Executive Function physiology
- Abstract
Interest in measuring executive function skills in young children in low- and middle-income country contexts has been stymied by the lack of assessments that are both easy to deploy and scalable. This study reports on an initial effort to develop a tablet-based battery of executive function tasks, which were designed and extensively studied in the United States, for use in Kenya. Participants were 193 children, aged 3-6 years old, who attended early childhood development and education centers. The rates of individual task completion were high (65-100%), and 85% of children completed three or more tasks. Assessors indicated that 90% of all task administrations were of acceptable quality. An executive function composite score was approximately normally distributed, despite higher-than-expected floor and ceiling effects on inhibitory control tasks. Children's simple reaction time (β = -0.20, p = .004), attention-related behaviors during testing (β = 0.24, p = .0005), and age (β = -0.24, p = .0009) were all uniquely related to performance on the executive function composite. Results are discussed as they inform efforts to develop valid and reliable measures of executive function skills among young children in developing country contexts.
- Published
- 2019
- Full Text
- View/download PDF
30. Where Does the Time Go? The Effect of Protocols for Stroke Last Known Well Documentation on Intravenous Recombinant Tissue Plasminogen Activator Delivery in the Northeast.
- Author
-
Zanichkowsky R, Nascimento JA, McCune M, Spencer C, Chukwuneke F, Wyrick T, and McCullough LD
- Subjects
- Documentation, Hospitals, Humans, Nursing Diagnosis, Practice Guidelines as Topic, Time Factors, United States, Fibrinolytic Agents therapeutic use, Guideline Adherence, Stroke drug therapy, Tissue Plasminogen Activator therapeutic use
- Abstract
Background: Despite significant efforts to improve thrombolytic use in the United States, only a small number of patients with ischemic stroke are currently treated. Although there are a number of contraindications to tissue plasminogen activator use, many patients are excluded because of the narrow therapeutic time window, which is determined by the "last known well" (LKW) time. However, it is unclear how the LKW is obtained and documented in the acute hospital setting., Methods: We surveyed hospitals throughout the Northeast region to determine if they had established protocols for documenting LKW times. Treatment rates as reported to Get with The Guidelines Stroke were then compared in hospitals with and without established protocols for documenting LKW times., Results: The majority of hospitals (73%) lacked established protocols for LKW documentation. Those without established protocols more often missed this variable when reporting to Get With The Guidelines-Stroke. Treatment rates were low overall (7%), although rates in patients who presented within 2 hours of symptom onset were high in hospitals whether they had an established protocol (86%) or not (87%). However, the lack of documentation of LKW is common and could influence the treatment rates if patients are erroneously excluded from treatment., Conclusions: Improved documentation of LKW times should be attempted. The addition of this variable to existing protocols could more accurately track the number of patients ineligible for treatment based on delayed presentation.
- Published
- 2016
- Full Text
- View/download PDF
31. Post-deposition bioink self-assembly: a quantitative study.
- Author
-
Shafiee A, McCune M, Forgacs G, and Kosztin I
- Subjects
- Computer Simulation, Humans, Time Factors, Tissue Scaffolds chemistry, Bioprinting methods, Ink
- Abstract
The outcome of a bioprinting process depends on both the deposition of the discrete bioink units and their ability to self-assemble into the desired structure following deposition. Post-printing structure formation is an autonomous process governed by fundamental biological organizing principles. As the quantitative formulation of such principles is notoriously difficult, bioprinting remains largely a trial and error approach. To address this problem, specifically in extrusion bioprinting, we have recently developed an effective computational method, the cellular particle dynamics (CPDs). We have demonstrated the predictive power of CPD in cases of simple printed constructs prepared with spherical multicellular bioink units. Here we generalize CPD to the important practical case of tubular grafts printed with cylindrical bioink units by taking into account the realistic experimental situation in which the length and the volume of the cylinders decrease post-printing. Based on our results, we provide a set of instructions for the use of CPD simulations to directly predict tubular graft formation without the need to carry out the corresponding complex and expensive control experiments. Using these instructions allows the efficient and timely biofabrication of tubular organ structures. A particularly instructive outcome of our analysis is that building tubular organ structures, such as vascular grafts by bioprinting can be done considerably faster by using cylindrical rather than spherical bionk units.
- Published
- 2015
- Full Text
- View/download PDF
32. Predictive modeling of post bioprinting structure formation.
- Author
-
McCune M, Shafiee A, Forgacs G, and Kosztin I
- Subjects
- Computer Simulation, Models, Biological, Tissue Engineering, Biophysics, Bioprinting, Cell Aggregation
- Abstract
Cellular particle dynamics (CPD) is an effective computational method to describe the shape evolution and biomechanical relaxation processes in systems composed of micro tissues such as multicellular aggregates. Therefore, CPD is a useful tool to predict the outcome of postprinting structure formation in bioprinting. The predictive power of CPD has been demonstrated for multicellular systems composed of identical volume-conserving spherical and cylindrical bioink units. Experiments and computer simulations were related through an independently developed theoretical formalism based on continuum mechanics. Here we generalize the CPD formalism to (i) include non-identical bioink particles often used in specific bioprinting applications, (ii) describe the more realistic experimental situation in which during the post-printing structure formation via the fusion of spherical bioink units the volume of the system decreases, and (iii) directly connect CPD simulations to the corresponding experiments without the need of the intermediate continuum theory inherently based on simplifying assumptions.
- Published
- 2014
- Full Text
- View/download PDF
33. High efficiency dye-sensitized solar cells based on three-dimensional multilayered ZnO nanowire arrays with "caterpillar-like" structure.
- Author
-
McCune M, Zhang W, and Deng Y
- Abstract
A 3D ZnO nanowire-based dye-sensitized solar cell (DSSC) with unique "caterpillar-like" structure was designed. Because of the significant improvement of the total ZnO nanowire surface area, the amount of light absorption was substantially increased. This increase in the light harvesting efficiency enables us to achieve an overall power conversion efficiency as high as 5.20%, which is the highest reported value to date for ZnO nanowire-based DSSCs. A branched-multilayered design of ZnO nanowire arrays grown from ZnO nanofiber seed layers proves to be very successful in fabricating 3D ZnO nanowire arrays. Practically, electrospun ZnO nanowires were used as the seeds in multilayer growth of ZnO nanowire arrays with a unique "caterpillar-like" structure. This unique structure significantly enhances the surface area of the ZnO nanowire arrays, leading to higher short-circuit currents. Additionally, this design resulted in closer spacing between the nanowires and more direct conduction pathways for electron transfer. Thus, the open-circuit voltage was so significantly improved as a direct result of the reduction in electron recombination.
- Published
- 2012
- Full Text
- View/download PDF
34. Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.
- Author
-
Devon KM, Vergara O, Victor JC, Swallow CJ, Cohen Z, Gryfe R, MacRae HM, McLeod RS, Murata A, Phang PT, Jones K, Merritt N, Belliveau P, Hurlbut D, Scheer A, Sabri E, Moloo H, Poulin EC, Mamazza J, Boushey R, Brown CJ, Zhang H, Gallinger S, Gryfe R, McLeod RS, Walters TD, Steinhart AH, Bernstein C, Tremaine W, Wolff BG, Ross S, Parkes R, McKenzie M, McLeod RS, Richardson D, deMontbrun S, McIntyre PB, Johnson PM, Shum J, Colquhoun PHD, Taylor BM, Polyhronopoulos GN, Feldman LS, McCluney AL, Buithieu J, Martinie J, Metrakos P, Fried GM, Chiasson PM, Burpee SE, Corrigan R, Manson P, Omiccioli A, Singh R, Hegge SG, McKinley CA, Lemieux P, Rhéaume P, Lévesque I, Bujold E, Brochu G, Mrad BA, Stoklossa CJ, Birch DW, Chen J, Christou NV, Turcotte S, Forget MA, Beauseigle D, Lapointe R, Garzon PM, Shah SA, Wei AC, Girgrah N, Levy GA, Wong P, Lilly LB, Grant DR, Cattral MS, McGilvary I, Greig PD, Tawadros PS, Wang Z, Birch S, Szaszi K, Kapus A, Rotstein OD, Mihailovic A, Nansamba C, Coyte P, Howar A, Urbach D, Govindarajan A, Cranford V, Wirtzfeld D, Gallinger S, Law CHL, Smith AJ, Gagliardi AR, Haggar F, Moloo H, Grimshaw J, Poulin EC, Mamazza J, Boushey RP, McConnell Y, Johnson P, Porter G, Govindarajan A, Kiss A, Rabeneck L, Smith AJ, Hodgson D, Law CHL, White C, Taylor MC, Borowiec AM, Fedorak RN, Polyhronopoulos GN, Feldman LS, Kaneva PA, Fried GM, Keshoofy M, Gutauskas A, Smith RF, Christou NV, Al-Sabah S, Ladouceur M, Christou NV, Thompson SK, Ruszkiewicz AR, Jamieson GG, Wijnhoven BPL, Game PA, Devitt PG, Watson DI, Poole B, Ehlen TG, Davis NL, Tuma F, Smith T, Hamoud M, Elfeitori A, Boushey R, Poulin E, Mamazza J, MacKenzie JR, Teel W, Reinhartz A, Schieman J, Brophy J, Hsu KE, Ferri LE, Feldman LS, Fried GM, Hsu KE, Man FY, Gizicki RA, Feldman LS, Fried GM, Taylor MC, Bruce S, Burtally A, Brochu G, Gagné JP, Martel G, Poulin EC, Mamazza J, Boushey RP, Deen S, Griffith O, Masoudi H, Wiseman SM, Cox H, Pasieka JL, Parr ZE, Thompson SK, Jamieson GG, Myers JC, Game PA, Devitt PG, Bélanger M, Brochu G, Moloo H, Haggar F, Grimshaw J, Coyle D, Graham ID, Sabri E, Poulin EC, Mamazza J, Balaa F, Stern H, Boushey RP, Moloo H, Sabri E, Wassif E, Haggar F, Poulin EC, Mamazza J, Boushey RP, Reso A, Estifanos D, Church N, Mitchell P, O'Neill C, Colquhoun P, Schlachta CM, Etemad-Rezai R, Jayaraman S, Passi R, Hodder AS, Pace DE, Chuah TK, Wirtzfeld D, Lee TYY, Pollett W, Trottier D, May G, Moloo H, Haggar F, Boushey R, Poulin E, Mamazza J, Singh R, Boutross-Tadross O, Deif B, Elias R, Stephen WJ, Omiccioli A, Singh R, Hegge SG, McKinley CA, Singh R, Omiccioli A, Hegge SG, McKinley CA, Sampath S, Segal BE, Carter JJ, Nguyen NH, Frimer M, Houston G, Bloom SW, Lemieux P, Couture C, Simard S, Lebel S, El Fitori A, Sabri E, Wassif E, Mamazza J, Poulin E, Boushey R, Warnock GL, Waddell J, Proctor G, Krajewski SA, Brown JA, Phang PT, Raval MJ, Brown CJ, Simunovic M, Major D, Qui F, To T, Baxter N, Urbach D, McGuire A, George R, Berg R, George R, Hristov H, McAlister ED, George R, Jones K, Bardell A, Isotalo P, Stotland PK, Chia S, Cyriac JS, Hagen JA, Klein LV, Hodgson N, Holowaty E, Lee G, Sussman J, Whelan T, Simunovic M, Apriasz I, Mohan S, Mccreery G, Patel R, Schlachta CM, Schlachta CM, Sorsdahl AK, Lefebvre KL, McCune ML, Hebbard PC, Wirtzfeld DA, Huynh QHP, Klein LV, Hagen JA, Xeroulis G, Dubrowski A, Leslie K, Mihailovic A, Howard A, Willan A, Coyte P, Urbach D, Sawisky G, Stoklossa CJ, Birch DW, Dickie BH, Stoklossa CJ, Davey D, Birch DW, Bohacek L, Pace DE, Karanicolas PJ, Colquhoun PH, Dahlke E, Guyatt GH, Butler MS, de Gara CJ, Boutros M, Zabalotny B, Charlin B, Meterissian S, Finley C, Clifton J, Fitzgerald M, Yee J, Quadri S, Knox J, Wong R, Xu W, Hornby J, Keshavjee S, Darling G, Schieman C, Tiruta C, Blitz M, Graham A, Gelfand G, McFadden S, Grondin S, de Perrot M, Anraku M, Feld R, Bezjak A, Burkes R, Roberts H, Cho J, Visbal A, Leighl N, Keshavjee S, Johnston M, Villeneuve PJ, Sundaresan RS, Gray DA, Rakovich G, Brigand C, Gaboury L, Martin J, Ferraro P, Duranceau A, Low D, Huang J, Cantone N, Schembre D, Mohan S, Trejos AL, Bassan H, Lin AW, Patel RV, Malthaner RA, Blitz M, Graham AJ, Gelfand G, McFadden SD, Grondin SC, Kondra J, Clifton J, Suarez G, Ross B, Evans K, Finley RJ, Yee J, Sugimura H, Spratt EH, Compeau CG, Shargall Y, Lara-Guerra H, Leighl N, Salvarrey A, Sakurada A, Paul N, Boerner S, Geddie W, Pond G, Shepherd FA, Tsao MS, and Waddell TK
- Published
- 2007
35. Aggressive tocolysis does not prolong pregnancy or reduce neonatal morbidity after preterm premature rupture of the membranes.
- Author
-
Combs CA, McCune M, Clark R, and Fishman A
- Subjects
- Adult, Case-Control Studies, Female, Fetal Membranes, Premature Rupture diagnosis, Follow-Up Studies, Gestational Age, Humans, Infant Mortality trends, Infant, Newborn, Maternal Age, Obstetric Labor, Premature prevention & control, Pregnancy, Pregnancy, High-Risk, Prospective Studies, Retrospective Studies, Risk Assessment, Treatment Outcome, Fetal Membranes, Premature Rupture drug therapy, Magnesium Sulfate therapeutic use, Pregnancy Complications diagnosis, Pregnancy Outcome, Tocolysis methods
- Abstract
Objective: This study was undertaken to evaluate whether aggressive tocolysis improves pregnancy outcome after preterm premature rupture of the membranes (PPROM)., Study Design: Retrospective case-control study of patients with PPROM before 34 weeks of gestation, followed by a prospective cohort study with historical controls. The retrospective phase covered 1995 through 1999 when we used tocolysis aggressively. With the use of survival analysis, we compared latency in our cases with 4 published control series in which tocolysis was never used. On the basis of the results, we adopted a new protocol in mid-2000 limiting tocolysis to 48 hours after betamethasone dosing and we conducted a 2-year prospective evaluation of this new protocol., Results: In the retrospective phase, tocolysis was used in 94% of 130 cases and maintained during 84% of 1162 total antenatal patient-days. There was no difference in latency between our cases and the published controls. One or more complications of tocolysis occurred in 18%. In the prospective study, 43% of 63 patients received tocolytics, but these were used at lower doses and were given during only 7% of 770 patient-days. Latency with this very limited tocolytic regimen (median 4.5 days, interquartile range 2.3 to 14.0) was not significantly different than during the last 24 months of aggressive tocolysis (median 3.8 days, 1.8 to 14 days, P=.16) and there were no differences in neonatal morbidity., Conclusion: Aggressive tocolysis after PPROM causes significant maternal morbidity, but does not increase latency or decrease neonatal morbidity compared with either very limited tocolysis or no tocolysis at all.
- Published
- 2004
- Full Text
- View/download PDF
36. Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma.
- Author
-
McCune MA, Winkelmann RK, Osmundson PJ, and Pineda AA
- Subjects
- Adult, Blood Pressure, Blood Proteins analysis, Blood Proteins physiology, Clinical Trials as Topic, Female, Follow-Up Studies, Humans, Immunoglobulins analysis, Immunoglobulins physiology, Middle Aged, Placebos pharmacology, Raynaud Disease therapy, Scleroderma, Systemic therapy, Plasma Exchange
- Abstract
Six female patients with stage I and II vascular scleroderma and Raynaud's phenomenon were treated with plasma exchange and placebo plasma exchange. Placebo exchange consisted of the return of the patient's own separated plasma. No consistent long-term objective improvement was demonstrated in patients treated with either plasma exchange or placebo plasma exchange. Immediate increases in pulse volume, digital blood pressure, and skin temperature occurred in some patients with both procedures. Mechanisms of change remain unexplained, and further study is warranted.
- Published
- 1983
- Full Text
- View/download PDF
37. Diabetes: what are the skin deep signs?
- Author
-
Millns JL, Fenske N, and McCune M
- Subjects
- Bacterial Infections etiology, Diabetes Complications, Gangrene, Humans, Skin Diseases, Infectious etiology, Diabetes Mellitus diagnosis, Skin Diseases etiology
- Published
- 1981
38. Laryngeal presentation of blastomycosis.
- Author
-
McCune MA, Rogers RS 3rd, and Roberts GD
- Subjects
- Adult, Biopsy, Blastomyces isolation & purification, Blastomycosis diagnosis, Blastomycosis microbiology, Carcinoma, Squamous Cell diagnosis, Diagnosis, Differential, Humans, Laryngeal Neoplasms diagnosis, Laryngitis diagnosis, Laryngitis microbiology, Male, Blastomycosis pathology, Laryngitis pathology
- Abstract
Systemic blastomycosis may rarely involve the larynx, and it most likely is a result of hematogenous dissemination or direct inoculation from a currently or previously active pulmonary infection. Often, laryngeal blastomycosis has been confused with squamous cell carcinoma because of the clinical and histopathologic similarities, and this confusion has led to inaccurate diagnosis and inappropriate therapy. The etiologic agent, Blastomyces dermatiditis, may be seen in infected tissue with routine and special stains; however, cultural proof remains the sine qua non for diagnosis.
- Published
- 1980
- Full Text
- View/download PDF
39. Smoking and esophageal pain.
- Author
-
McCune M and Lehman G
- Subjects
- Humans, Esophageal Diseases etiology, Pain etiology, Smoking complications
- Published
- 1976
- Full Text
- View/download PDF
40. Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride.
- Author
-
McCune MA, Perry HO, Muller SA, and O'Fallon WM
- Subjects
- Administration, Oral, Arginine administration & dosage, Clinical Trials as Topic, Double-Blind Method, Electrolytes blood, Herpes Simplex blood, Herpes Simplex diet therapy, Herpes Simplex pathology, Humans, Lysine administration & dosage, Prospective Studies, Random Allocation, Recurrence, Herpes Simplex drug therapy, Lysine therapeutic use
- Abstract
In a prospective, randomized, double-blind, placebo-controlled, cross-over study of forty-one patients we found that oral ingestion of 1,248 mg a day of L-Lysine monohydrochloride shows evidence of decreasing the recurrence rate of herpes simplex attacks in nonimmunocompromised hosts. A dose of 624 mg a day was not effective. L-Lysine may also be capable of decreasing the severity of symptoms associated with recurrences. Neither dosage showed any evidence of shortening the healing time compared to placebo.
- Published
- 1984
41. Eosinophilic enteritis associated with chronic eosinophilic pneumonia.
- Author
-
Marnocha KE, Maglinte DD, Kelvin FM, McCune M, Weiser DC, and Strate R
- Subjects
- Adult, Enteritis diagnostic imaging, Enteritis pathology, Eosinophilia diagnostic imaging, Eosinophilia pathology, Female, Humans, Intestine, Small diagnostic imaging, Intestine, Small pathology, Lung diagnostic imaging, Lung pathology, Pulmonary Eosinophilia diagnostic imaging, Pulmonary Eosinophilia pathology, Radiography, Enteritis complications, Eosinophilia complications, Pulmonary Eosinophilia complications
- Abstract
A case of eosinophilic pneumonia and eosinophilic infiltration of the small bowel and colon is reported. The patient presented with nonspecific chest and abdominal symptoms, and lack of response to therapy for presumed pneumonia. Further investigation including lung, muscle, and gastrointestinal tract biopsies revealed eosinophilic infiltration of the lung and gastrointestinal tract, an association that does not appear to have been previously documented.
- Published
- 1986
42. Sonographic findings on chronic intussusception in the adult.
- Author
-
Chua GT, Maglinte DT, Graffis R, McCune M, and Krol K
- Subjects
- Adult, Chronic Disease, Female, Humans, Ileal Diseases diagnosis, Intussusception diagnosis, Jejunal Diseases diagnosis, Ultrasonography
- Published
- 1981
43. The effect of intravenous nutrition on muscle mass and exercise capacity in perioperative patients.
- Author
-
Wood CD, Glover J, McCune M, Hendricks J, Johns M, and Pollard M
- Subjects
- Adult, Aged, Aged, 80 and over, Body Water analysis, Body Weight, Energy Intake, Humans, Male, Middle Aged, Nitrogen metabolism, Parenteral Nutrition, Total methods, Potassium metabolism, Serum Albumin analysis, Muscles pathology, Parenteral Nutrition methods, Physical Exertion, Surgical Procedures, Operative
- Abstract
This study was undertaken to compare the efficacy of four different types of perioperative intravenous nutritional support. Fifty-five patients undergoing routine major surgery were studied. They were prospectively assigned to one of four study groups. Group 1 received formal total parenteral nutrition (90 g amino acids, 3,000 calories as glucose, per day); Group 2, 100 g glucose per day; Group 3, 90 g amino acids per day; and Group 4, peripheral parenteral nutrition (90 g amino acids plus 1,600 calories, 60 percent as fat per day). Group 1 was maintained on therapy for 3 weeks and the other groups for 8 days. Nitrogen balance, maintenance of body cell mass, serum albumin levels, and maintenance of exercise capacity were measured. Patients receiving peripheral parenteral nutrition maintained their nutritional parameters, as did those receiving total parenteral nutrition. These infusions were both markedly superior to those receiving glucose alone or those receiving amino acids alone. Nitrogen balance was not correlated with maintenance of function, but maintenance of body cell mass was correlated with maintenance of exercise capacity (r = 0.66, p less than or equal to 0.01). We conclude that perioperative peripheral parenteral nutrition, in contradistinction to hypocaloric infusions of glucose or amino acids, is capable of maintaining postoperative muscle mass and function close to preoperative levels after major surgery, and in situations of relatively mild surgical stress, approaches the efficacy of total parenteral nutrition in this regard. A significant correlation exists between changes in body cell mass determined from isotope dilution and changes in the exercise capacity of large muscle masses.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.